Shattuck Announces Additional Positive Data From Phase 1B Study Of SL-172154 With Azacitidine

(RTTNews) - Shattuck Labs, Inc. (STTK) Friday announced additional positive interim data from the Phase 1B study of SL-172154 in combination with Azacitidine (AZA) in frontline higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML) patients.

Objective response rate (ORR), percentage of people who have a partial response or complete response to the treatment, was 67 percent in HR-MDS patients, primarily with TP53 mutations, who were treated with SL-172154 plus AZA. 42 percent patients achieved a complete remission (CR) with 3.6 months as the median time to CR.

ORR was 43 percent in frontline TP53m AML patients, and 29 percent of patients achieved a CR.

Further, SL-172154 demonstrated a manageable interim safety profile in combination with AZA

"Enrollment is now underway for our randomized, controlled expansion cohort in frontline HR-MDS patients, and we expect to engage in regulatory discussions later this year regarding the registrational strategy for SL-172154," said Lini Pandite, Chief Medical Officer of Shattuck.